Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
Completed · Phase 1
Conditions studied: Healthy Subjects
In brief
This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.
Key facts
- Study ID
- NCT00814060
- Run by
- Puma Biotechnology, Inc.
- People needed
- 24
- Starts
- 2009-01-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2012-05-14
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Tacoma, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.